Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness of Cup a 1 Immunotherapy for Patients with Moderate to Severe Allergic Rhinoconjunctivitis with or without Controlled Asthma

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for patients with allergic rhinoconjunctivitis, which is an allergic reaction that affects the nose and eyes, and may also include patients with controlled asthma. The treatment being tested is an immunotherapy using a purified protein called Cup a 1, which is derived from the pollen of the Cupressus arizonica tree, commonly known as Arizona cypress. This study aims to evaluate the effectiveness and safety of this treatment in reducing allergy symptoms in patients who are sensitive to Cupressaceae pollen.

Participants in the study will be randomly assigned to receive either the Cup a 1 treatment or a placebo, which is a substance with no active therapeutic effect. Neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, ensuring that the results are unbiased. The treatment will be administered as a suspension for injection under the skin, known as subcutaneous use. The study will take place over two pollen seasons, during which participants will complete questionnaires to report the frequency and severity of their symptoms.

The primary goal of the study is to assess how well the Cup a 1 treatment works in reducing allergy symptoms compared to the placebo. This will be measured by a combination of symptom scores and medication use. Secondary goals include evaluating the number of symptom-free and medication-free days, as well as any additional doctor visits or emergencies related to the allergies. The study will also monitor any side effects and changes in specific immune markers in the participants. The trial is expected to continue until March 2025.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a skin test to check for sensitivity to Cupressaceae pollen and Cup a 1 protein.

    A blood test is performed to measure specific IgE levels, which should be 2 kU/l or higher.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either the treatment or a placebo. Neither the participants nor the researchers know which group each participant is in.

  3. Step 3

    Treatment administration

    The treatment involves subcutaneous injections of the purified protein Cup a 1 or a placebo. The placebo consists of a saline solution with mannitol and histamine.

    Injections are administered at regular intervals as specified in the study protocol.

  4. Step 4

    Monitoring and follow-up

    Participants are monitored for symptom frequency and severity. This includes completing a questionnaire during two successive pollen seasons.

    Regular follow-up visits are scheduled to assess the control of asthma and allergic rhinitis, using tools like the ACT and modified ARIA.

  5. Step 5

    Evaluation of outcomes

    The primary outcome is the efficacy of the treatment, evaluated through symptom scores and the Combined Symptom and Medication Score (CSMS).

    Secondary outcomes include the frequency of symptom-free days, medication-free days, and any adverse events.

  6. Step 6

    End of trial

    The trial is expected to conclude by March 31, 2025. Final assessments will be conducted to evaluate the overall efficacy and safety of the treatment.

Who can join the trial?

8 criteria

  • Must be a male or female between the ages of 12 and 65.
  • Must provide informed consent to participate in the study. If the participant is a minor, consent must also be obtained from legal guardians or representatives.
  • Must have moderate or severe **allergic rhinitis** (inflammation of the nose due to allergies) or **rhinoconjunctivitis** (inflammation of the nose and eyes due to allergies), with or without controlled asthma, and must be sensitized to **Cupresaceae** (a type of plant family).
  • Must have **IgE levels** (a type of antibody related to allergies) for **Cupressus** or **Cup a 1** that are 2 kU/l or higher, which corresponds to classes 3 to 6.
  • Must have a positive **skin prick test** (a test where a small amount of allergen is placed on the skin to see if there is a reaction) with a diameter of 3 mm or more for **Diater extract of Cupressaceae arizónica** and **Cup a 1**, conducted at the initial visit.
  • Must have clinically relevant symptoms when exposed to **Cupresaceae**.
  • Must be willing to follow all study requirements and be available for follow-up throughout the trial.
  • For women who can become pregnant, a negative urine pregnancy test is required, and they must agree to use effective birth control from 14 days before the first dose until 30 days after the last dose. This applies to women from the start of menstruation to postmenopause, unless they have been sterilized through procedures like hysterectomy (removal of the uterus), bilateral salpingectomy (removal of both fallopian tubes), and bilateral oophorectomy (removal of both ovaries).

Who cannot join the trial?

8 criteria

  • Patients who have a severe allergic reaction to the treatment being studied.
  • Patients with a history of severe asthma that is not well controlled.
  • Patients who are pregnant or breastfeeding.
  • Patients with any other medical condition that the study doctors think might make it unsafe for them to participate.
  • Patients who are currently participating in another clinical trial.
  • Patients who have received another investigational drug within the last 30 days.
  • Patients with a history of drug or alcohol abuse.
  • Patients who are unable to comply with the study procedures.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Cup a 1 is a purified and isolated protein used in immunotherapy. It is administered through injections under the skin. This therapy is designed for patients who have moderate to severe allergic reactions, specifically allergic rhino conjunctivitis, which may or may not be accompanied by controlled asthma. The goal of this treatment is to help the body build a tolerance to the allergen, which in this case is related to the Cupressaceae family of plants.

What is already known about the treatment

Cup a 1 – This medication is administered through subcutaneous injections and is currently being evaluated in a phase III clinical trial. It is used for treating moderate to severe allergic rhinoconjunctivitis, with or without controlled asthma, in patients sensitized to Cupressaceae allergens. The main therapeutic indication is to reduce allergic symptoms by desensitizing the immune system to the specific allergen. At the molecular level, Cup a 1 works by gradually introducing the purified allergen to the body, aiming to modify the immune response and decrease sensitivity. It is classified under specific immunotherapy agents.

Investigated diseases

Allergic rhinoconjunctivitis – This condition is characterized by inflammation of the nasal passages and eyes due to an allergic reaction. It typically occurs when the immune system overreacts to allergens such as pollen, dust, or pet dander. Symptoms include sneezing, runny or stuffy nose, itchy eyes, and watery eyes. The condition often follows a seasonal pattern, especially during pollen seasons. Over time, symptoms may vary in intensity and can be influenced by exposure to specific allergens. It is a common condition and can affect individuals of all ages.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-519527-14-00Protocol codeDIA-EC-Cupa1-01-22Estimated enrolment150 patientsSponsorDiater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).